Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699-Reference-Cited by-同舟云学术

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

Published:2010-10-26 Issue:10 Volume:103 Page:1588-1596
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Daniel R A,Rozanska A L,Mulligan E A,Drew Y,Thomas H D,Castelbuono D J,Hostomsky Z,Plummer E R,Tweddle D A,Boddy A V,Clifford S C,Curtin N J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605946.pdf

Reference33 articles.

1. Ali M, Telfer BA, McCrudden C, O’Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ (2009) Vasoactivity ofAG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 15: 6106–6112

2. Barone G, Maurizi P, Tamburrinin G, Riccardi R (2006) Role of temozolomide in paediatric brain tumours. Childs Nerv Syst 22: 652–661

3. Baruchel S, Diezia M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42: 2335–2342

4. Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A, for the Pediatric Brain Tumor Consortium. (2007) Phase I trial of single-dosetemozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13: 6712–6718

5. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, North M, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang L-Z, Webber SE, Williams KJ, Curtin NJ (2004) Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 96: 56–67

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis;Journal of Medicinal Chemistry;2023-10-16

2. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor;Biomedicine & Pharmacotherapy;2023-07

3. Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma;Oncology Reports;2023-05-05

4. The PARP inhibitor Rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth;Neuro-Oncology Advances;2023-01-01

5. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors;Current Treatment Options in Oncology;2022-10-15